8-K: Paysign Reports Strong Q1 2025 Results Driven by Patient Affordability Growth

Paysign's Q1 2025 results showcase significant revenue and Adjusted EBITDA growth, fueled by a surge in the patient affordability business.

Summary

• Paysign reported total revenues of $18.60 million for Q1 2025, a 41.0% increase compared to Q1 2024.
• Net income for Q1 2025 was $2.59 million, or $0.05 per diluted share, significantly higher than the $309 thousand, or $0.01 per diluted share, in Q1 2024.
• Adjusted EBITDA for Q1 2025 reached $4.96 million, a 193.3% increase from $1.69 million in the same period last year.
• The company's patient affordability revenue increased by 260.8% year-over-year, while plasma revenue decreased by 9.2% due to industry-wide oversupply.
• Paysign added 14 net patient affordability programs in Q1 2025, bringing the total to 90 active programs.
• The company exited the quarter with $6.85 million in unrestricted cash and no bank debt, while repurchasing 100,000 shares of common stock for $376 thousand.
• Paysign is revising its full-year 2025 revenue guidance to $72.0 million to $74.0 million, with Adjusted EBITDA expected to be between $16.0 million and $17.0 million.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong financial results, increased guidance, and optimistic management commentary. The growth in the patient affordability segment is particularly encouraging.

Positives

• Significant revenue growth driven by the patient affordability segment.
• Substantial increase in net income and Adjusted EBITDA.
• Strong growth in the number of patient affordability programs.
• Healthy cash position with no bank debt.
• Share repurchase program demonstrating confidence in the company's value.
• Increased full-year revenue and Adjusted EBITDA guidance.
• Gross profit margin increased approximately 10 percentage points to 62.9% versus 52.6%.

Negatives

• Plasma revenue decreased by 9.2% due to industry-wide oversupply.
• Gross dollar load volume and gross spend volume were down 4.5% and 9.4%, respectively, over first quarter 2024.
• Cashflows decreased $10.85 million from December 31, 2024, largely related to increased accounts receivable balances related to the growth of our patient affordability programs.

Risks

• Continued decline in plasma revenue could impact overall financial performance.
• The company's reliance on the patient affordability business makes it vulnerable to changes in that market.
• The company acknowledges that a downturn in the economy, including as a result of COVID-19 and variants, as well as further government stimulus measures, could reduce our customer base and demand for our products and services, which could have an adverse effect on our business, financial condition, profitability and cash flows.
• Operating in a highly regulated environment could impact the business.
• Failure by us or business partners to comply with applicable laws and regulations could impact the business.
• Changes in the laws, regulations, credit card association rules or other industry standards affecting our business could impact the business.
• A data security breach could expose us to liability and protracted and costly litigation.

Future Outlook

Paysign expects total revenues for 2025 to be in the range of $72.0 million to $74.0 million, with Adjusted EBITDA between $16.0 million and $17.0 million. For the second quarter of 2025, the company anticipates revenue between $18.5 million and $19.0 million and Adjusted EBITDA between $4.5 million and $5.0 million.

Management Comments

• 'Q1 2025 was another exceptional quarter for Paysign, as we achieved record revenue, operating income and Adjusted EBITDA,' said Mark Newcomer, President and CEO of Paysign.
• Jeff Baker, Paysign CFO, stated that they expect to be on an annual run rate for cash cost savings of $4.0 million to $5.0 million by the end of the second quarter.

Industry Context

Paysign's performance is notable in the context of the broader financial services and healthcare technology industries. The company's growth in patient affordability solutions aligns with the increasing demand for accessible healthcare payment options. The decline in plasma revenue reflects industry-wide challenges related to plasma inventories.

Comparison to Industry Standards

• Paysign's 41% revenue growth in Q1 2025 significantly outpaces the average growth rate for companies in the payment processing sector, which typically ranges from 10-20%.
• Companies like Global Payments Inc. and Fiserv Inc., while much larger, have shown more moderate growth rates in their recent quarterly reports.
• The 193.3% increase in Adjusted EBITDA is also exceptional compared to industry peers, indicating strong operational efficiency and profitability improvements.
• In the patient affordability space, companies like ConnectiveRx and RxBenefits are key competitors, but Paysign's growth rate suggests it is gaining market share effectively.
• The company's gross profit margin of 62.9% is competitive with other fintech companies, such as Block Inc. and PayPal Holdings Inc., which typically have margins in the 50-70% range.

Stakeholder Impact

• Shareholders will benefit from the increased revenue, profitability, and share repurchase program.
• Employees may see increased opportunities due to the company's growth.
• Customers will benefit from the expanded capabilities and integrated payment solutions.
• Suppliers may see increased demand due to the company's growth.
• Creditors are likely to view the company favorably due to its strong financial position.

Next Steps

• Focus on streamlining operations and expanding the capabilities of the Gamma Innovation platform.
• Integrating engagement technology into existing payment solutions.
• Reducing reliance on third-party professional services.
• Continuing to monitor trends in the plasma business and capitalize on opportunities in the patient affordability market.

Key Dates

Keywords

Paysign, financial results, patient affordability, plasma, prepaid card programs, digital banking, payment processing, Adjusted EBITDA, revenue, earnings